This case series looks at the actions taken by NGOs, local campaigners and the Indian government, against Roche over its patent for a breast cancer drug “Trastuzumab”, otherwise known as “Herceptin”, Herceptin was an expensive but highly effective treatment for some types of breast cancer and campaigners were vocal in arguing that in emerging markets, such as India, it was beyond the means of the majority of the population. Case A covers the campaign and actions until December 2012. Although Roche reduced the price of Herceptin and entered into an agreement with a local company to produce a generic version at a lower price, the campaign for greater access continued.
This case series looks to understand how NGOs and local campaigners can affect a company’s ability to market its products or operate in emerging markets.
Roche, Health Care, Pharmaceuticals
IMD retains all proprietary interests in its case studies and notes. Without prior written permission, IMD cases and notes may not be reproduced, used, translated, included in books or other publications, distributed in any form or by any means, stored in a database or in other retrieval systems. For additional copyright information related to case studies, please contact Case Services.
Research Information & Knowledge Hub for additional information on IMD publications